On August 27, CANSINOBIO fell 5.04% in regular trading, trading at HK$33.7/share, with turnover of HK$95.72 million. The decline comes as the stock retreats from a sharp rally earlier in the week driven by its mRNA cancer vaccine strategic cooperation announcement.

On August 25, the company announced that its subsidiary signed a strategic cooperation framework agreement with deepGeneAI to jointly develop personalized mRNA therapeutic cancer vaccines, targeting gastrointestinal solid tumors and rare cancers globally. The news propelled shares up approximately 18% on August 26, compounding a prior 48.59% single-day surge on August 20 following Moderna and Merck's successful Phase 3 mRNA cancer vaccine trial. CLSA noted that CANSINOBIO's development pathway and antigen design are broadly similar to Moderna's platform.

However, the company previously issued a cautionary announcement stating that mRNA is only one of its technology platforms and that no undisclosed material information exists. The current framework agreement covers early-stage R&D collaboration, with commercialization timelines still uncertain. Today's board meeting is also scheduled to review interim results, adding to near-term uncertainty.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)